Mode
Text Size
Log in / Sign up
N/A N=108 Randomized Quadruple-blind Treatment

Defining Adolescent Nausea Through Brain Imaging and Neurostimulation Response

Functional Gastrointestinal Disorders

Enrolled (actual)
108
Serious AEs
0.0%
Results posted
Jun 2023
Primary outcome: Primary: Nausea Severity Scale — 2.18; 2.45 units on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Active Auricular Neurostimulation (Device); Sham Auricular Neurostimulation (Device)
Age
Pediatric, Adult · 11+ yrs
Sex
All
Sponsor
Medical College of Wisconsin
Primary completion
Feb 2022

Outcome Measures

OutcomeResultp-value
PRIMARY
Nausea Severity Scale
2.18; 2.45
SECONDARY
Nausea Profile
33.33; 28.43
SECONDARY
Baxter Retching Faces Scale
2.29; 3.43

Summary

This study evaluates the efficacy of auricular neurostimulation via an non-invasive percutaneous electrical nerve field stimulator (PENFS) in adolescents with functional nausea. A neurostimulator is applied to the outer ear and stimulates several nerves that are thought to be involved in transmission of nausea and vomiting signals. Half of the study subjects will receive an active nerve stimulator while the other half will receive an inactive one.

Eligibility Criteria

Inclusion Criteria

  • Meeting pediatric Rome IV criteria for functional nausea
  • English-speaking and able to verbalize their condition and concerns about nausea, pain and other symptoms
  • Lack of other explanation for symptoms
  • Intact external ear that is free of infection or severe dermatological conditions, - - No currently implanted electrical device

Exclusion Criteria

  • Medically complex and/or suffering from medical condition that may explain symptoms
  • Taking a medication that may explain symptoms
  • Significant developmental delays
  • Patients treated with a new drug affecting the central nervous system within 4 weeks of study start
  • Infection or severe dermatological condition of ear
  • Currently implanted electrical device
  • Patients with a history of severe allergy to adhesives
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03675321). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search